Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.58 USD
Change Today -0.18 / -6.52%
Volume 380.0
VSCP On Other Exchanges
As of 8:10 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

virtualscopics inc (VSCP) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/18/14 - $5.85
52 Week Low
04/16/15 - $2.55
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VIRTUALSCOPICS INC (VSCP)

Related News

No related news articles were found.

virtualscopics inc (VSCP) Related Businessweek News

No Related Businessweek News Found

virtualscopics inc (VSCP) Details

VirtualScopics, Inc. provides imaging solutions to the pharmaceutical, biotechnology, and medical device industries. The company offers a suite of image analysis software tools and applications, which are used in detecting and measuring specific anatomical structures and metabolic activity using medical images. Its proprietary software and algorithms provide measurement capabilities designed to improve clinical research and development. The company’s image-based measurement and visualization tools enable automated, accurate, and reproducible measurement of minute changes that occur in anatomic structures in musculoskeletal, oncological, cardiological, and neurological diseases. It has strategic alliances with PPD, Inc. to provide clients with an integrated and customized clinical development and medical imaging solution for oncology clinical trials; and IXICO, plc. to provide imaging contract research services related to clinical trials of drugs and medical devices across a range of therapeutic areas and modalities. VirtualScopics, Inc. was founded in 2000 and is headquartered in Rochester, New York.

85 Employees
Last Reported Date: 03/31/15
Founded in 2000

virtualscopics inc (VSCP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $385.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $175.2K
Compensation as of Fiscal Year 2014.

virtualscopics inc (VSCP) Key Developments

VirtualScopics, Inc. and IXICO plc and Micron, Inc. Enters into Collaboration Agreement

VirtualScopics Inc. and IXICO plc and Micron Inc. jointly announced that they have entered into a collaboration agreement enhancing each company's global clinical trial imaging solution offerings to Pharma and Biopharma companies. The collaboration agreement with Micron, together with previously signed Alliance Framework Agreement with IXICO, will enable VirtualScopics to continue gaining presence with top Pharma companies and strengthen global Phase III capabilities in the market place. This expands the IXICO’s Alliance's reach and capabilities internationally and especially in Asia where it offers the opportunity to build on existing client base in Japan, China and Korea. This signed collaboration agreement will allow Micron to expand its services outside of Japan to the markets of North America and Europe.

VirtualScopics Inc. Appoints Andrew Levitch to the Audit Committee and Michael Woehler

On March 2, 2015, the board of directors of VirtualScopics Inc. appointed Andrew Levitch to the Audit Committee and Michael Woehler to the Compensation and Personnel Committee. Mr. Woehler was originally elected as a director by the Board on February 6, 2015. Mr. Levitch was elected as director on February 10, 2015 by the holders of the Company's Series C-1 Preferred Stock.

VirtualScopics Inc. Announces Consolidated Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

VirtualScopics Inc. announced consolidated unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenues of $2,709,511 against $2,706,910 a year ago. Operating loss was $1,089,147 against $1,017,480 a year ago. Net loss available to common stockholders was $1,130,996 against $1,056,558 a year ago. Basic and diluted loss per share was $0.38 against $0.35 a year ago. For the full year, the company reported total revenues of $10,452,484 against $11,174,051 a year ago. Operating loss was $3,423,563 against $2,763,731 a year ago. Net loss available to common stockholders was $3,590,423 against $2,912,541 a year ago. Basic and diluted loss per share was $1.20 against $0.98 a year ago. The increase in net loss for the 2014 periods is primarily related to VirtualScopics' increased investments in infrastructure, sales and marketing, systems, training and human capital while supporting the current business.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VSCP:US $2.58 USD -0.18

VSCP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ICON PLC $64.31 USD -1.77
PAREXEL International Corp $63.68 USD -1.07
PRA Health Sciences Inc $29.07 USD -0.295
View Industry Companies

Industry Analysis


Industry Average

Valuation VSCP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.8x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VIRTUALSCOPICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at